12月19日，A股创新药板块迎来久违的集体反弹。早盘益方生物大幅拉升近10%，新活威涨超13%，亚红医药涨超10%，悦康药业亦跟涨超6%，板块内多数个股飘红，情绪明显回暖。这一走势并非偶然，消息面上，新版国家医保目录近日公布，新增111种5年内新上市药品，其中50个为1类新药，数量与比例均创历史新高。政策面对创新药的支持力度持续加大，医保目录动态调整机制逐步常态化，为创新药的商业化落地打开了更明确...
Source Link12月19日，A股创新药板块迎来久违的集体反弹。早盘益方生物大幅拉升近10%，新活威涨超13%，亚红医药涨超10%，悦康药业亦跟涨超6%，板块内多数个股飘红，情绪明显回暖。这一走势并非偶然，消息面上，新版国家医保目录近日公布，新增111种5年内新上市药品，其中50个为1类新药，数量与比例均创历史新高。政策面对创新药的支持力度持续加大，医保目录动态调整机制逐步常态化，为创新药的商业化落地打开了更明确...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.